Slope Raised $20M to Revolutionize Clinical Trial Operations through Automation

Slope, the clinical operations solution company, raised $20M. The funding was led by the global venture capital firm New Enterprise Associates, Inc. (NEA).


Slope is set to accelerate go-to-market efforts and further expand its technology-driven infrastructure solution to coordinate and automate clinical trial supply chains for decentralized and direct-to-patient clinical trials with the funds received. Slope's infrastructure solution addresses the operational problems and delays caused by manual, spreadsheet-driven clinical trial management processes.

Slope's software-assisted workflows are powered by real-time supply chain data. This data collected from all clinical trial stakeholders ClinOps teams, CROs, research sites, patients, vendors, and laboratories is automatically coordinated with the thousands of logistical transactions that occur throughout the lifecycle of a study. It also gathers and records relevant metadata through a 21 CFR Part 11 compliant software platform ensuring a fully traceable chain of custody regardless of study design for all drugs, devices, lab kits, samples, and equipment.

"Finding an investment partner with first-hand knowledge of the problems caused by the inefficiencies of current clinical trial supply chain management processes was a key success factor for us at Slope," said Rust Felix, Slope CEO and co-founder. "With its expansive life sciences portfolio and deep domain expertise, NEA was at the top of our list. We are very excited to have them alongside us as we revolutionize clinical trial operations."